Original Research Article
Year: 2018 | Month: December | Volume: 8 | Issue: 12 | Pages: 13-17
Histomorphological Correlation of Oropharyngolaryngeal Dysplasia and Squamous Cell Carcinoma with Special Reference to P53 and PCNA Expression
Priyanka Gupta1, Kishore Shaw2, Prasanna Kumar Satpathy3, Raghumani Mohanty4
1Consultant Pathologist, 12, Nakari Mondal Road; Kanchrapara, 24PGS(North), West Bengal, India.
2Asstt Professor, Medicine, COM &J.N.M. Hospital, WBUHS, Kalyani, Nadia, West Bengal, India
3Professor &HOD, Pathology, Hi-Tech Medical College & Hospital, Bhubaneswar, Odisha, India
4Professor, Pathology, Hi-Tech Medical College & Hospital, Bhubaneswar, Odisha, India
Corresponding Author: Priyanka Gupta
Background: Despite advances in surgery, radiotherapy and chemotherapy over the past three decades, no significant improvement in the prognosis for oral cancer has been observed. This could change if the cancer can be detected at an early stage. Aim: To evaluate the p53 and PCNA (Proliferative cell nuclear antigen) expression as an indicator for clinical aggressiveness in dysplasia and squamous cell carcinoma (SCC) in oropharyngolaryngeal (OPL) region.
Materials and Methods: 50 histopathologically diagnosed patients were taken from the oral pathology department of our institute. It comprised of 15 dysplasia cases and 35 SCC cases of OPL region. Immunohistochemistry was done to investigate the expression of p53 and PCNA and scored based on percentage of positive tumor cells and the staining intensity.
Results: The expression of p53 and PCNA was detected in 34(68%) and 50(100%) cases respectively. There was significant increase in staining intensity and percentage of tumor cells expressing p53 and PCNA from dysplasia to different grades of SCC.
Conclusion: Present study concluded that p53 and PCNA expression can be used to assess the potential for malignant transformation in dysplasia and aggressiveness in different grades of SCC of OPL region.
Key words: Dysplasia, Squamous cell carcinoma, Oropharyngolaryngeal region, p53, PCNA